Ruxolitinib Alternatives Compared
| Ruxolitinib | Hydroxyurea | Jakafi (ruxolitinib) |
|
|---|
| Ruxolitinib | Hydroxyurea | Jakafi (ruxolitinib) |
|
|||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Prescribed for Polycythemia Vera, Myelofibrosis, Myeloproliferative Disorders, Graft Versus Host Disease. Ruxolitinib may also be used for purposes not listed in this medication guide. |
Prescription only
Prescribed for Chronic Myelogenous Leukemia, Sickle Cell Anemia, Glioblastoma Multiforme, Cervical Cancer, Head and Neck Cancer, Plaque Psoriasis, Polycythemia Vera, Psoriasis, Psoriatic Arthritis... View more |
Prescription only
Prescribed for Polycythemia Vera, Myelofibrosis, Myeloproliferative Disorders, Graft Versus Host Disease. Jakafi may also be used for purposes not listed in this medication guide. |
Related suggestions Polycythemia Vera
Popular comparisons
|
|||||||||||||||
| More about Ruxolitinib | More about Hydroxyurea | More about Jakafi (ruxolitinib) | ||||||||||||||||
| Ratings & Reviews | ||||||||||||||||||
|
Ruxolitinib has an average rating of 7.3 out of 10 from a total of 43 ratings on Drugs.com. 65% of reviewers reported a positive effect, while 16% reported a negative effect. |
Hydroxyurea has an average rating of 7.0 out of 10 from a total of 47 ratings on Drugs.com. 60% of reviewers reported a positive effect, while 21% reported a negative effect. |
Jakafi has an average rating of 7.5 out of 10 from a total of 33 ratings on Drugs.com. 67% of reviewers reported a positive effect, while 15% reported a negative effect. |
||||||||||||||||
| Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | ||||||||||||||||||
|
View all Ruxolitinib side effects |
View all Hydroxyurea side effects |
View all Jakafi side effects |
||||||||||||||||
| Drug Class | ||||||||||||||||||
| Generic Availability | ||||||||||||||||||
|
N/A |
Lower cost generic |
|||||||||||||||||
| Pricing and Coupons * Prices are without insurance | ||||||||||||||||||
|
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
View all Hydroxyurea prices |
View all Jakafi prices |
||||||||||||||||
| Dosage Forms | ||||||||||||||||||
|
N/A |
|
|
||||||||||||||||
| Brand Names | ||||||||||||||||||
| Jakafi | Droxia, Hydrea, Siklos, Xromi |
N/A |
||||||||||||||||
| Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | ||||||||||||||||||
|
5.8 hours |
4 hours |
5.8 hours |
||||||||||||||||
| CSA Schedule 1 View glossary of CSA terms | ||||||||||||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||
| Pregnancy Category | ||||||||||||||||||
|
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
Category D
Positive evidence of risk
See the full pregnancy warnings document. |
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
||||||||||||||||
| Drug Interactions | ||||||||||||||||||
|
A total of 513 drugs are known to interact with Ruxolitinib:
|
A total of 289 drugs are known to interact with Hydroxyurea:
|
A total of 513 drugs are known to interact with Jakafi:
|
||||||||||||||||
| Alcohol/Food/Lifestyle Interactions | ||||||||||||||||||
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
|
||||||||||||||||
| Disease Interactions | ||||||||||||||||||
| First Approval Date | ||||||||||||||||||
|
November 16, 2011 |
December 07, 1967 |
November 16, 2011 |
||||||||||||||||
| WADA Class View classifications | ||||||||||||||||||
|
N/A |
N/A |
N/A |
||||||||||||||||
| More Information | ||||||||||||||||||
| Patient Resources | ||||||||||||||||||
| Professional Resources | ||||||||||||||||||
| Related Treatment Guide | ||||||||||||||||||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
See also:
Jakafi
Jakafi is used to treat certain types of myelofibrosis or polycythemia vera in adults, and certain ...
Besremi
Besremi (ropeginterferon alfa-2b-njft) is used for the treatment of adults with polycythemia vera ...
Botox
Botox is used for cosmetic purposes and to treat overactive bladder symptoms, urinary incontinence ...
Alecensa
Alecensa (alectinib) is an oral kinase inhibitor that may be used to treat certain types of ...
Alunbrig
Alunbrig (brigatinib) is used to treat anaplastic lymphoma kinase-positive (ALK+) metastatic ...
Augtyro
Augtyro (repotrectinib) is a next-generation TKI (Tyrosine Kinase Inhibitor) cancer medicine used ...
Ayvakit
Ayvakit (avapritinib) is a prescription medicine used for the treatment of gastrointestinal stromal ...
Balversa
Balversa (erdafitinib) is an oral kinase inhibitor that may be used to treat adults with locally ...
Braftovi
Braftovi is a targeted cancer treatment used in combination with Mektovi, mFOLFOX6, or Erbitux, to ...
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.